Meeder Asset Management Inc. boosted its stake in shares of Iqvia Holdings Inc (NYSE:IQV) by 562.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,959 shares of the medical research company’s stock after purchasing an additional 14,399 shares during the period. Meeder Asset Management Inc.’s holdings in Iqvia were worth $2,201,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the stock. Commerce Bank lifted its position in Iqvia by 4.2% during the third quarter. Commerce Bank now owns 232,796 shares of the medical research company’s stock valued at $30,203,000 after purchasing an additional 9,317 shares during the period. Private Advisor Group LLC lifted its position in Iqvia by 51.3% during the third quarter. Private Advisor Group LLC now owns 5,002 shares of the medical research company’s stock valued at $649,000 after purchasing an additional 1,696 shares during the period. Signition LP lifted its position in Iqvia by 373.7% during the third quarter. Signition LP now owns 14,992 shares of the medical research company’s stock valued at $1,945,000 after purchasing an additional 11,827 shares during the period. Valeo Financial Advisors LLC lifted its position in Iqvia by 67.8% during the third quarter. Valeo Financial Advisors LLC now owns 1,728 shares of the medical research company’s stock valued at $208,000 after purchasing an additional 698 shares during the period. Finally, State Board of Administration of Florida Retirement System lifted its position in Iqvia by 1.6% during the third quarter. State Board of Administration of Florida Retirement System now owns 217,094 shares of the medical research company’s stock valued at $28,166,000 after purchasing an additional 3,428 shares during the period. Institutional investors own 91.36% of the company’s stock.
Shares of IQV stock opened at $122.37 on Wednesday. Iqvia Holdings Inc has a 12 month low of $91.57 and a 12 month high of $135.48. The company has a market cap of $24.62 billion, a price-to-earnings ratio of 28.07, a price-to-earnings-growth ratio of 1.75 and a beta of 0.81. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.09 and a quick ratio of 1.09.
Iqvia (NYSE:IQV) last announced its quarterly earnings data on Monday, October 22nd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.03. The firm had revenue of $2.59 billion during the quarter, compared to analysts’ expectations of $2.58 billion. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. Iqvia’s revenue for the quarter was up 5.2% on a year-over-year basis. As a group, research analysts predict that Iqvia Holdings Inc will post 5.13 earnings per share for the current year.
A number of research analysts recently weighed in on IQV shares. Royal Bank of Canada restated a “$110.25” rating and set a $128.00 price objective on shares of Iqvia in a research report on Thursday, July 19th. Zacks Investment Research cut shares of Iqvia from a “buy” rating to a “hold” rating in a report on Monday, August 20th. Raymond James upped their target price on shares of Iqvia from $136.00 to $145.00 and gave the company a “strong-buy” rating in a report on Friday, August 31st. Robert W. Baird upped their target price on shares of Iqvia from $143.00 to $146.00 and gave the company an “outperform” rating in a report on Tuesday, October 2nd. Finally, Mizuho set a $120.00 target price on shares of Iqvia and gave the company a “hold” rating in a report on Monday, August 6th. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $131.67.
In other news, insider Kevin C. Knightly sold 9,216 shares of the stock in a transaction on Friday, September 7th. The shares were sold at an average price of $126.46, for a total value of $1,165,455.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John G. Danhakl sold 370,470 shares of the stock in a transaction on Wednesday, September 12th. The stock was sold at an average price of $124.83, for a total transaction of $46,245,770.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 601,586 shares of company stock valued at $75,510,422. Corporate insiders own 6.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/iqvia-holdings-inc-iqv-shares-bought-by-meeder-asset-management-inc.html.
Iqvia Company Profile
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Further Reading: Growth Stocks, What They Are, What They Are Not
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.